HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

被引：0
|
作者：
E Rakovitch
S Nofech-Mozes
W Hanna
S Narod
D Thiruchelvam
R Saskin
J Spayne
C Taylor
L Paszat
机构：
[1] University of Toronto,Department of Radiation Oncology University of Toronto
[2] Sunnybrook Health Sciences Centre,Department of Pathology
[3] University of Toronto,undefined
[4] 2075 Bayview Avenue,undefined
[5] Toronto M4N 3M5,undefined
[6] Canada,undefined
[7] Institute of Clinical Evaluative Sciences,undefined
[8] University of Toronto,undefined
[9] Women's College Hospital Research Institute,undefined
[10] University of Toronto,undefined
来源：
British Journal of Cancer | 2012年 / 106卷
关键词：
DCIS; biomarkers; recurrence; breast-conserving surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1160 / 1165
页数：5
相关论文
共 50 条
  • [41] Expression of HER2/Neu in Ductal Carcinoma In Situ and Its Correlation with Clinical Pathological Factors
    Xu, J.
    Parker, K. M.
    MODERN PATHOLOGY, 2014, 27 : 89A - 89A
  • [42] SALVAGE TREATMENT FOR LOCAL RECURRENCE FOLLOWING BREAST-CONSERVING SURGERY AND DEFINITIVE IRRADIATION FOR DUCTAL CARCINOMA IN-SITU (INTRADUCTAL CARCINOMA) OF THE BREAST
    SOLIN, LJ
    FOURQUET, A
    MCCORMICK, B
    HAFFTY, B
    RECHT, A
    SCHULTZ, DJ
    BARRETT, W
    FOWBLE, BL
    KUSKE, R
    TAYLOR, M
    MCNEESE, M
    AMALRIC, R
    KURTZ, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (01): : 3 - 9
  • [43] HER-2/neu over-expression as a predictor of invasive breast cancer in patients with ductal carcinoma in situ
    Roses, R. E.
    Paulson, E. C.
    Strode, C.
    Sharma, A.
    Schueller, J. E.
    Weinstein, S.
    Fox, K.
    Zhang, P.
    Czerniecki, B. J.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 25 - 25
  • [44] High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy
    Yamazaki, N.
    Wada, N.
    Yamauchi, C.
    Yoneyama, K.
    EJSO, 2015, 41 (05): : 617 - 624
  • [45] Microinvasion is not associated with an increased risk of local recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy
    Rakovitch, E.
    Pignol, J-P
    Hanna, W.
    Chartier, C.
    Kahn, H.
    Wong, J.
    Paszat, L.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S69 - S69
  • [46] An Evaluation of HER2 Positivity in Invasive Breast Cancers with Associated Ductal Carcinoma In Situ
    Thalheimer, L.
    Lloyd, J.
    Edina, G.
    Nolano, S.
    Carter, W. B.
    Frazier, T.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S56 - S56
  • [47] Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy
    Kestin, LL
    Goldstein, NS
    Lacerna, MD
    Balasubramaniam, M
    Martinez, AA
    Rebner, M
    Pettinga, J
    Frazier, RC
    Vicini, FA
    CANCER, 2000, 88 (03) : 596 - 607
  • [48] Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ - evaluating HER2 in synchronous in-situ and invasive carcinoma
    Hui, Yiang
    Lu, Shaolei
    Wang, Hai
    Resnick, Murray B.
    Wang, Yihong
    HISTOPATHOLOGY, 2019, 74 (02) : 358 - 362
  • [49] Mammographic features of local recurrence in women who have undergone breast-conserving therapy for ductal carcinoma in situ
    Liberman, L
    VanZee, KJ
    Dershaw, DD
    Morris, EA
    Abramson, AF
    Samli, B
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1997, 168 (02) : 489 - 493
  • [50] Radiologic evaluations and invasive procedures following breast-conserving surgery in a large cohort of women with ductal carcinoma in situ
    Nekhlyudov, L.
    Habel, L.
    Achacoso, N.
    Jung, I.
    Haque, R.
    Schnitt, S.
    Fletcher, S. W.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 : 119 - 119
12345